LYRA Key Statistics, Chart & Performance
The current stock price of LYRA is 4.01 USD. In the past month the price decreased by -30.26%. In the past year, price decreased by -62.68%.
LYRA Latest News, Press Relases and Analysis
LYRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About LYRA
Company Profile
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
Company Info
LYRA THERAPEUTICS INC
480 Arsenal Way
Watertown MASSACHUSETTS 02472 US
CEO: Maria Palasis
Employees: 30
Phone: 16173734600
LYRA THERAPEUTICS INC / LYRA FAQ
What does LYRA do?
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-05-01. The firm is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The firm is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).
What is the current price of LYRA stock?
The current stock price of LYRA is 4.01 USD. The price increased by 7.51% in the last trading session.
Does LYRA THERAPEUTICS INC pay dividends?
LYRA does not pay a dividend.
What is the ChartMill rating of LYRA THERAPEUTICS INC stock?
LYRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for LYRA stock?
The Revenue of LYRA THERAPEUTICS INC (LYRA) is expected to decline by -50.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does LYRA THERAPEUTICS INC have?
LYRA THERAPEUTICS INC (LYRA) currently has 30 employees.
What is the ownership structure of LYRA THERAPEUTICS INC (LYRA)?
You can find the ownership structure of LYRA THERAPEUTICS INC (LYRA) on the Ownership tab.
LYRA Technical Analysis
LYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LYRA. LYRA has a bad profitability rating. Also its financial health evaluation is rather negative.
LYRA Financial Highlights
Over the last trailing twelve months LYRA reported a non-GAAP Earnings per Share(EPS) of -22.89. The EPS increased by 69.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.38% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LYRA Forecast & Estimates
9 analysts have analysed LYRA and the average price target is 23.46 USD. This implies a price increase of 485.04% is expected in the next year compared to the current price of 4.01.
For the next year, analysts expect an EPS growth of 72.46% and a revenue growth -50.15% for LYRA